Skip to main content
TipRanks
Go Ultimate75% OFF

GeneFerm Biotechnology Co. Ltd. (1796) AI Stock Analysis

TW:1796

GeneFerm Biotechnology Co. Ltd.

(TPEx:1796)

Select Model
Rating:52Neutral
Price Target:TWD 27.00â–¼(-5.26% Downside)
Action:initiatedcoverage
Date:11/10/26

The overall score is constrained by weak technical momentum and a stretched valuation. The stock is in a clear downtrend, trading below all major moving averages with bearish momentum indicators, while a P/E of 68.6 is difficult to justify given the company's volatile earnings history. Positively, the financial recovery in 2025 provides a foundation of improved profitability and a healthy balance sheet, but this fundamental improvement has not yet translated into positive market sentiment or a reasonable valuation.

Positive Factors
Profitability ReboundThe return to positive earnings indicates that the business has regained operating viability after the 2024 loss. Although profitability is not yet at prior peaks, renewed earnings provide an improved base for reinvestment, resilience, and sustained financial performance over coming quarters.
Negative Factors
Subdued ProfitabilityThe earnings rebound remains incomplete because current margins are far below the stronger levels achieved in 2022–2023, while return on equity is modest. This limits the company’s ability to generate attractive returns from its asset and capital base and leaves results vulnerable to further pressure.

GeneFerm Biotechnology Co. Ltd. (1796) vs. SPDR S&P 500 ETF (SPY)

-50%-40%-30%-20%-10%0%10%20%TW:1796-37.52%SPY+14.55%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
TWD 1.18B
Dividend Yield
2.46%
Average Volume (3M)
20.12K
Price to Earnings (P/E)
163.0
Beta (1Y)
0.23
Revenue Growth
7.05%
EPS Growth
―
Country
TW
Employees
288
Sector
General
Sector Strength
55
Industry
Drug Manufacturers - Specialty & Generic

GeneFerm Biotechnology Co. Ltd. Business Overview & Revenue Model

Company Description

GeneFerm Biotechnology Co., Ltd. specializes in the development, production, and global distribution of fermented health and wellness products, serving both the Taiwanese domestic market and international clients. The company's extensive product line...

GeneFerm Biotechnology Co. Ltd. Financial Statement Overview

Summary

Financial performance reflects a recovery year with revenue rebounding 30% and a return to profitability. The balance sheet is healthy with low leverage (D/E 0.40). However, cash flow conversion is moderate (63% of net income), and historical volatility in revenue and margins tempers the overall strength.

Income Statement

62Positive

Balance Sheet

68Positive

Cash Flow

55Neutral
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue669.49M677.10M521.16M793.77M633.96M522.33M
Gross Profit160.07M190.80M96.75M286.35M222.16M192.65M
EBITDA85.75M115.40M56.34M231.09M163.34M124.51M
Net Income7.28M28.86M-22.53M124.62M93.45M57.41M
Balance Sheet
Total Assets1.22B1.28B1.15B1.18B1.19B1.32B
Cash, Cash Equivalents and Short-Term Investments223.23M280.26M122.45M120.15M100.69M539.61M
Total Debt308.16M324.23M246.19M127.44M219.16M464.70M
Total Liabilities435.15M464.00M358.31M282.54M358.86M569.22M
Stockholders Equity779.96M816.66M788.18M892.84M830.77M747.66M
Cash Flow
Free Cash Flow15.47M75.89M-14.61M118.91M-155.98M-33.37M
Operating Cash Flow54.35M99.31M8.09M190.31M122.43M112.23M
Investing Cash Flow-89.51M-22.59M-22.83M-70.62M-280.33M-145.25M
Financing Cash Flow-68.77M81.06M16.38M-99.87M-281.79M224.81M

GeneFerm Biotechnology Co. Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

TW:1796 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
TW:1796TW:179652NeutralTWD 1.18B163.04―2.46%7.05%―
TW:4133TW:413348NeutralTWD 1.20B26.82―0.56%-5.00%2002.36%
TW:6578TW:657842NeutralTWD 1.19B-49.57―2.41%21.50%-5.51%
TW:6496TW:649633UnderperformTWD 1.08B-5.77――11.64%-10.83%

* General Sector Average

Performance Comparison

-40%-20%0%20%40%TW:1796TW:4133TW:4195TW:6496TW:6564TW:6578Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TW:1796 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TW:1796GeneFerm Biotechnology Co. Ltd.28.50-18.48-39.34%
TW:4133Abnova Taiwan Corp.19.85-3.47-14.89%
TW:4195Genomics BioSci & Tech. Co., Ltd.14.60-9.60-39.67%
TW:6496Excelsior Biopharma Inc22.95-6.20-21.27%
TW:6564Enimmune corporation14.95-5.67-27.49%
TW:6578Dabomb Protein Biotech Corporation16.60-1.75-9.54%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026